In molecular imaging research, the development of multimodal imaging probes has recently attracted much attention. In the present study, we prepared radioiodinated BODIPY and applied it as a nuclear and optical dual functional labeling agent for proteins and peptides. We designed and synthesized [ The in vivo quantitative detection of the biodistribution of biologically active proteins and peptides plays an important role in a wide range of research in life science. In such research, the in vivo pharmacokinetics of proteins and peptides labeled with radionuclides or fluorescent dye are determined using a nuclear or optical imaging technique. Nuclear imaging techniques including positron emission tomography (PET) and single photon emission computed tomography (SPECT) constitute some of the most common clinical imaging modalities because they can offer a variety of important information on the in vivo biodistribution of radiolabeled, biologically active proteins and peptides 1, 2
The in vivo quantitative detection of the biodistribution of biologically active proteins and peptides plays an important role in a wide range of research in life science. In such research, the in vivo pharmacokinetics of proteins and peptides labeled with radionuclides or fluorescent dye are determined using a nuclear or optical imaging technique. Nuclear imaging techniques including positron emission tomography (PET) and single photon emission computed tomography (SPECT) constitute some of the most common clinical imaging modalities because they can offer a variety of important information on the in vivo biodistribution of radiolabeled, biologically active proteins and peptides 1, 2 . In contrast, optical imaging with fluorescent probes has become a versatile modality that has been used for clinical intraoperative tumor detection and in vivo imaging studies using small animals 3 . Since both nuclear and optical imaging methods have distinctive characteristics appropriate for clinical application, a dual modality imaging system that combines these two imaging techniques may noninvasively provide complementary information for the diagnosis of various diseases. Many dual imaging probes that can be applied to such nuclear and optical dual modality imaging have been reported [4] [5] [6] [7] [8] [9] [10] [11] . Among them, Li et al. recently investigated the radiofluorination of BODIPY, which is one of the well-known fluorescent dyes (Fig. 1 ) 12 . They reported that one of two fluorine atoms in the boron center of BODIPY can be used for radiofluorination, and applied [ 18 F] BODIPY as a dual modality imaging agent for the first time (Fig. 1) . [ 18 F]BODIPY is an attractive dual imaging agent because it can be integrated with positron emission tomography and the optical properties of the imaging agent in the same molecule. Several dual imaging probes with [ 18 F]BODIPY including [
18 F]BODIPY ® FL-RGD ( Fig. 1 ) have been reported [13] [14] [15] . However, the relatively short half-life of 18 F. In numerous studies regarding the chemistry of BODIPY 16 , we found that it is possible to introduce iodine into pyrrole rings of the BODIPY scaffold 17, 18 . Since iodine has several radionuclides, including , it can be applied to broad research from basic research to diagnostic imaging and clinical radiotherapy in consideration of their half-life and characteristics of radiation 19 . Therefore, we considered that radioiodinated BODIPY can be used to develop a new method for the dual functional labeling of biologically active peptides and proteins.
In the present study, we synthesized radioiodinated BODIPY ([ 123/125 I]BODIPY) and applied it as a nuclear and optical dual functional labeling agent. We selected bovine serum albumin (BSA), RGD peptide, and trastuzumab as a model protein, peptide, and biologically active protein, respectively, to validate the basic concept for the development of new dual functional probes based on the radioiodinated BODIPY, and evaluated the feasibility of using [ (2) , which was synthesized according to a method reported previously (Fig. 3) 17 . We efficiently prepared [ 125 I]2 at a radiochemical yield of 75.1% with a radiochemical purity of >99% after purification by HPLC. This efficiency of radiolabeling was similar to that obtained with the conventional radioiodination including electrophilic reactions with activated aromatic groups, and iodo-demetalation of aryls and alkyenes, using organotin or silicon precursors 19, 20 . 
30%ID/g of [
125 I]2 accumulated in the liver at 2 min postinjection. High radioactivity accumulation was also observed in the heart (12%ID/g) and lungs (25%ID/g) at 2 min postinjection. Thereafter, the radioactivity observed in the liver, heart, and lungs was gradually excreted into the intestine, and the radioactivity in the intestine reached 20%ID/g at 60 min postinjection. No marked radioactivity accumulation in the thyroid or stomach was observed, suggesting that [ 125 I]2 showed high stability against the deiodination reaction in vivo in addition to (Fig. 8) . We also attempted radioiodination with a different method using hydrogen peroxide as the oxidant, similarly to the method used in the However, we could not obtain [ 125 I]4 at high yields in this reaction, probably because the hydrolysis of the NHS ester of compound 3 occurred due to a reaction with water. Therefore, we changed to the condition of the radioiodination reaction to avoid using water as a solvent. Although we used methanol as a solvent in this reaction, no marked methyl esterification was observed.
Next, we used [ 125 I]4 for a conjugation reaction with proteins and peptides. In the present study, we firstly selected BSA and RGD peptide as a model protein and peptide, respectively, for dual labeling with [ (Fig. 9) . Furthermore, when we determined the fluorescence at an emission of 520 nm, the fluorescent peak was detected at a similar elution volume to that of absorbance and radioactivity (Fig. 9) . To determine whether [ (Fig. 11) . The results for the conjugation reaction of [ 125 I]4 with BSA and RGD peptide also support the feasibility of nuclear and optical dual functional labeling of various other biologically active proteins and peptides including antibodies, antibody fragments, and other carriers including liposomes, micelles, and polymer conjugates 22, 23 . Then, we applied this conjugation reaction to the labeling of trastuzumab with [
125 I]4 as one of the examples of biologically active proteins and peptides. Trastuzumab is an antibody against human epidermal growth factor receptor 2 (HER2) that is overexpressed in several cancers, and commonly used as a carrier protein of radioisotopes and fluorescence dyes for the in vivo imaging of cancers 24, 25 . According to the similar method used for the conjugation reaction of BSA, we reacted [
125 I]4 with trastuzumab, and purified the reaction mixture with size-exclusion chromatography. As shown in Fig. 12 , the elution volume where the radioactivity peak was detected corresponded to that of UV absorption where intact trastuzumab was eluted, indicating that trastuzumab was labeled with [ 14 and S1), suggesting that 123 4 may function as a radiolabeling agent without any loss of biological activity of an antibody. Since no marked radioactivity accumulation was observed in the thyroid (Fig. S1B), [ 123 I]4 shows high stability against in vivo deiodination reactions even after conjugation with an antibody, suggesting that radioiodine may stably bind to the BODIPY scaffold in vivo. In the present study, we did not perform in vivo fluorescence imaging due to the relatively low excitation and emission wavelengths of BODIPY 4 that are inadequate for in vivo fluorescent imaging. However, the successful SPECT imaging with 
Conclusions
In this study, for the first time, we revealed that radioiodinated BODIPY can function as a new agent useful for the nuclear and optical dual functional labeling of various biologically active proteins and peptides. Since iodine has several radioisotopes with various features suitable for use in fields from basic research to clinical application, proteins and peptides labeled with radioiodinated BODIPY may be applied quartet (q). ESI mass spectrometry was conducted with a Shimadzu LCMS-2020. High-resolution mass spectrometry (HRMS) was conducted with JMS-700V (JEOL). High-performance liquid chromatography (HPLC) was performed with Shimadzu system (an LC-20AD pump with an SPD-20A UV detector, λ = 254 nm) using a Cosmosil C 18 column (Nacalai Tesque, COSMOSIL 5C 18 -AR-II 4.6 mm I.D. × 150 mm) and CH 3 CN/H 2 O (60: 40) as the mobile phase at a flow rate of 1.0 mL/min. HER2-expressing human gastric cancer cells (N87) were purchased from DS Pharma Biomedical (Osaka, Japan).
Chemistry. Compounds 1, 2, and 3 were synthesized according to the previous procedures reported by Wang et al. 26 , Chen et al.
17
, and Nepomnyashchii et al. 27 , respectively. -8-(4-(N-succinimidoxycarbonyl)phenyl)−1,3,7,9-tetramethyl-BODIPY (4) . To a solution of BODIPY derivative 3 (100.0 mg, 0.21 mmol) in CH 2 Cl 2 (25 mL), N-iodosuccinimide (NIS) (48.4 mg, 0.21 mmol) in CH 2 Cl 2 (10 mL) was added dropwisely and the reaction mixture was stirred at 0 °C for 30 min. After the addition, the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated under a vacuum. The residue was purified by silica gel chromatography (CHCl 3 /n-hexane = 10/1) to provide 68.7 mg of 4 at a yield of 54.1%. RGD peptide conjugated with 4 (4-RGD). 4-RGD was synthesized according to a method reported previously 15 . BODIPY derivative 4 (0.89 mg, 1.5 µmol) and c(RGDyK) (0.40 mg, 0.65 µmol, used as RGD) in DMSO (50 µL) were mixed and N,N-diisopropylethylamine (5 µL) was added to the mixture. After 3-h incubation, the reaction mixture was purified by reversed-phase HPLC. The flow rate was 1 mL/min, with the mobile phase starting from 90% solvent A (0.1% TFA in water) and 10% solvent B (0.1%TFA in CH 3 CN) to 0% solvent A and 100% solvent B at 20 min. 125 I]2 (50 µL in a mixed solvent of 90% saline and 10% EtOH, 0.11-0.22 MBq) was diluted with freshly prepared murine plasma (250 µL). The solution was incubated at 37 °C for 24 h. After the addition of acetonitrile (600 µL) and vortexing, the mixture was centrifuged (4 °C, 10,000 g, 5 min). The supernatant was filtered and the filtrate was analyzed by reversed-phase HPLC using a COSMOSIL column (5C 18 AR-II) with an isocratic solvent of CH 3 SPECT/CT study. N87 (human gastric cancer cell) tumor-bearing mice were prepared as reported previously 28 .
2-Iodo
[ 123 I]4-trastuzumab (2.2-4.1 MBq/ 60-150 μg, 150 μL PBS) was intravenously injected into the N87 tumor-bearing mice (n = 3). The mice were anesthetized by isoflurane (2-2.5%), and SPECT and CT images were obtained using the U-SPECT-II/CT system (MILabs, Utrecht, the Netherlands) with 0.6-mm pinhole collimators (SPECT conditions: 60 min × 1 frame; CT conditions: accurate full angle mode in 65 kV/615 μA) at 8 and 24 h after injection of [
123 I]4-trastuzumab. SPECT images were reconstructed using the OSEM method (8 subset, 1 iteration) with a 0.6-mm Gaussian filter.
